Compare HCTI & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCTI | ALZN |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 4.1M |
| IPO Year | 2021 | 2021 |
| Metric | HCTI | ALZN |
|---|---|---|
| Price | $2.18 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 255.6K | 153.4K |
| Earning Date | 04-16-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,891,000.00 | N/A |
| Revenue This Year | $79.33 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $0.01 | $0.51 |
| 52 Week High | $20.42 | $8.22 |
| Indicator | HCTI | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 40.71 |
| Support Level | $2.18 | $0.84 |
| Resistance Level | $2.68 | $2.57 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 17.64 | 67.57 |
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their effort to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Platform Services.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.